Skip to content

Topical Irrigation Therapy for CRS

Efficacy and Safety of Adjuvant Topical Irrigation in the Treatment of Acute Exacerbation of Chronic Rhinosinusitis Following Functional Endoscopic Sinus Surgery (FESS)

Status
Terminated
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02630472
Acronym
QSIND
Enrollment
10
Registered
2015-12-15
Start date
2015-10-31
Completion date
2017-05-04
Last updated
2019-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinitis, Sinusitis

Brief summary

The purpose of the study is to evaluate the physiologic response of quinine-saline irrigations for acute exacerbation of uncomplicated chronic rhinosinusitis following endoscopic sinus surgery. Subjects who have previously had functional endoscopic sinus surgery with acute exacerbation of chronic rhinosinusitis will be randomized to either a quinine-saline or saline-placebo arm. The investigators will measure baseline and follow-up clinical and quality-of-life outcomes for both arms, and then compare the groups at the end of the study period. The investigators' hypothesis is that the participants in the quinine sulfate arm will perform better on all measures as compared to the control arm.

Detailed description

Overall Objectives: To evaluate the physiological differences between quinine-saline irrigations vs. saline-placebo irrigations for acute exacerbation of uncomplicated chronic rhinosinusitis following endoscopic sinus surgery. A secondary objective is to determine if the use of quinine is efficacious as an alternative therapy to treat bacterial rhinosinusitis. Background: Sinusitis is a common disorder accounting for an estimated 13 million physician office visits in the United States each year. The aggregated cost of sinusitis is approximately $8 billion annually, affecting an estimated 16% of the population in the United States. Despite multiple attempted treatments, including an estimated 550,000 surgeries per year, the disease continues to be a major health problem, both in expenditures and poor quality of life. Recent analysis of data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey from 2006 to 2010 showed that rhinosinusitis accounted for more outpatient antibiotic prescriptions in adults than any other diagnosis. Chronic rhinosinusitis (CRS) represents a considerable subset of this population and accounts for a significant portion of expenditures and the vast majority of surgeries. It is defined as signs and symptoms of sinusitis lasting more than 12 weeks. Unlike the organisms responsible for acute rhinosinusitis, difficult to treat bacteria such as Pseudomonas aeruginosa, Staphylococcus aureus and Stenotrophomonas multiformia are often offending pathogens in CRS. Their prevalence increases in those patients who have already had sinus surgery and continue to get recurring sinus infections. Staph aureus and gram-negative organisms have been shown to account for roughly 60% of infections in those patients who have previously undergone endoscopic sinus surgery. Due to increasing drug resistance as well as the potential for biofilm formation, there has been an increasing pressure from both patients and clinicians alike to develop alternative treatments to systemic antibiotics. One commonly used alternative in patients who have had previous sinus surgery is topical saline irrigation with and without other topical preparations. Topical irrigations have much greater paranasal sinus penetration in post surgical patients. Commonly used topical preparations include: saline alone or saline mixed with mupirocin, gentamicin, tobramycin, ceftazadine, betadine, manuka honey, baby shampoo, budesonide or mometasone. The investigators have recently identified a novel arm of upper airway innate immunity mediated by bitter taste receptors. When a subset of airway bitter taste receptors are activated they stimulate the respiratory epithelium to generate nitric oxide, an important component of sinus innate immunity that increases mucociliary clearance as well as diffuses into the mucus where it is bactericidal. A topical therapy to activate these taste receptors may help the sinuses clear infections through this natural innate defense mechanism. While the investigators have identified multiple bitter compounds that stimulate this response, quinine piqued our interest as it activates multiple bitter taste receptors and has already been used in the human nose.

Interventions

Our plan is to first study quinine against saline to determine efficacy and safety. The vast majority of patients with rhinosinusitis utilize low pressure / high volume (240mls) sinonasal lavage to cleanse the sinonasal cavity. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. In standard tonic water, quinine is 8.3mg/100mls and thus an 8oz glass of Canada Dry tonic water has 19.6mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. To put this in context, the therapeutic range of quinine to treat malaria is 10mg/kg true ileal digestibility (TID) (2100mg for a 70kg individual) nearly 200 X the dose the investigators are proposing.

DRUGPlacebo

In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.

Sponsors

University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients who have undergone Functional Endoscopic Sinus Surgery (FESS) 2. Purulent drainage on nasal endoscopy 3. Male or female subjects, 18 years of age or older 4. Patients seen at the Dept. of Otorhinolaryngology clinic at Hospital of the University of Pennsylvania (HUP), a tertiary care clinic

Exclusion criteria

1. Pregnant women 2. Immunocompromised patients 3. Granulomatous diseases with rhinologic manifestations (Wegner's, Sarcoid, Churg-Strauss) 4. Primary ciliary dyskinesia

Design outcomes

Primary

MeasureTime frameDescription
Change in Microbiome ProfileBaseline, Week 2, and Week 10Pre and post treatment endoscopically-obtained sinonasal microbiologic cultures.

Secondary

MeasureTime frameDescription
Change in Lund-Kennedy Endoscope ScoreBaseline, Week 2, and Week 10Pre and post treatment nasal endoscopy scored with a validated staging system for edema, -scored by an independent blind observer.
Change in the 22-item Sinonasal Outcomes Test ScoreBaseline, Week 2, and Week 10Pre and post treatment quality of life questionnaires (22-item Sinonasal Outcomes Test \[SNOT-22\]).
Change in Sniffin' Stick-12 ScoreBaseline, Week 2 and Week 10Change in olfactory sense from baseline to week 10 will be measured using the Sniffin' Stick-12 system. Patients will smell each sniffing pen and record the smell they detect. A score between 0-12 will indicate olfactory sense.

Other

MeasureTime frameDescription
Rescue AntibioticsWeek 2 and Week 10The necessity for rescue oral antibiotics for persistent infection.

Countries

United States

Participant flow

Participants by arm

ArmCount
Quinine Sulfate
Each participant in the experimental arm will receive 28 tubes with 1mg/ml (6 mls total) of quinine sulfate, as well as 28 3cc syringes with the atomizers. The solutions will be light-protected. Patients will apply 3 mls to each nostril twice per day. Patients will be exposed to 12.0 mg quinine per day. The Investigational Drug Service (IDS) will prepare and record the distribution of the irrigant. The Clinical Research Coordinator or Clinical Research Nurse will pick up the solutions and will demonstrate the application. The application of the solution is exactly the same as their daily regimen. Quinine Sulfate: Our plan is to first determine efficacy and safety. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. The therapeutic range of quinine to treat malaria is nearly 200 X the dose proposed.
10
Placebo
The placebo arm will be spiked with Sucrose Octaacetate which has a bitter taste, but does not stimulate sinonasal nitric oxide production. Each study participant will receive 28 tubes with 0.5mg/ml sucrose octaacetate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be in light-protected tubes. The placebo arm will mirror the experimental arm exactly, except for the treatment solution contained in the vials. Placebo: In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
0
Total10

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyPhysician Decision100

Baseline characteristics

CharacteristicQuinine SulfatePlaceboTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
10 Participants0 Participants10 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants
Race (NIH/OMB)
White
10 Participants10 Participants
Region of Enrollment
United States
10 Participants10 Participants
Sex: Female, Male
Female
6 Participants6 Participants
Sex: Female, Male
Male
4 Participants4 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 0
other
Total, other adverse events
7 / 100 / 0
serious
Total, serious adverse events
0 / 100 / 0

Outcome results

Primary

Change in Microbiome Profile

Pre and post treatment endoscopically-obtained sinonasal microbiologic cultures.

Time frame: Baseline, Week 2, and Week 10

Population: This study was terminated. Partial data was collected and is misleading due to mis-dosing. This outcome measure was not evaluated.

Secondary

Change in Lund-Kennedy Endoscope Score

Pre and post treatment nasal endoscopy scored with a validated staging system for edema, -scored by an independent blind observer.

Time frame: Baseline, Week 2, and Week 10

Population: This study was terminated. Partial data was collected and is misleading due to mis-dosing. This outcome was not measured.

Secondary

Change in Sniffin' Stick-12 Score

Change in olfactory sense from baseline to week 10 will be measured using the Sniffin' Stick-12 system. Patients will smell each sniffing pen and record the smell they detect. A score between 0-12 will indicate olfactory sense.

Time frame: Baseline, Week 2 and Week 10

Population: This study was terminated. Partial data was collected and is misleading due to mis-dosing. This outcome was not measured.

Secondary

Change in the 22-item Sinonasal Outcomes Test Score

Pre and post treatment quality of life questionnaires (22-item Sinonasal Outcomes Test \[SNOT-22\]).

Time frame: Baseline, Week 2, and Week 10

Population: This study was terminated. Partial data was collected and is misleading due to mis-dosing. This outcome was not measured.

Other Pre-specified

Rescue Antibiotics

The necessity for rescue oral antibiotics for persistent infection.

Time frame: Week 2 and Week 10

Population: This study was terminated. Partial data was collected and is misleading due to mis-dosing. This outcome was not measured.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026